Insys To Pay $150M To End DOJ Scrutiny Of Opioid-Rx Bribes

Law360 (August 8, 2018, 3:17 PM EDT) -- Opioid manufacturer Insys Therapeutics Inc. has agreed to pay at least $150 million for the U.S. Department of Justice to drop its criminal investigation and civil claims that the company bribed doctors to prescribe its under-the-tongue fentanyl spray, the company announced Wednesday.

Insys' former executives are facing criminal charges separate from the probe of the company. Insys founder John Kapoor, left, is shown leaving Boston federal court in November after pleading not guilty to conspiracy and bribery charges. (Alison Noon/Law360)

The Arizona-based drugmaker, whose former executives are separately facing criminal charges in Massachusetts federal court, said it could pay an additional...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!